Healthcare, Pharma & Life Sciences

Shanghai – November 06, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has dosed the first patient in China in the Phase I ATTRACT study of ATG-201, its CD19 x CD3 bispecific T-cell engager (TCE) for adult patients with B cell-mediated autoimmune diseases. UCB holds worldwide exclusive rights to develop, manufacture and commercialize the asset.

UCB holds global rights while Antengene runs Phase I in China and Australia

Under the agreement, UCB also gains access to the manufacturing technology associated with ATG-201. Antengene remains responsible for conducting the Phase I trials in China and Australia.

The Australian arm has cleared its regulatory steps. ATG-201 has obtained approval from the Human Research Ethics Committee (HREC) and completed the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA).

Tampa – November 06, 2026 -- Medicare will pay a national non-facility (office) rate of approximately $19,441 for CPT code 27279 starting January 1, 2027, according to PainTEQ's reading of the CMS Calendar Year 2027 Physician Fee Schedule Final Rule (CMS-1848-F). The code covers percutaneous or minimally invasive sacroiliac (SI) joint arthrodesis using devices with intrinsic fixation that pierce the cortices. It had no office rate before that date.

CMS finalizes practice expense inputs that create the first office rate for 27279

Under the 2026 Physician Fee Schedule, code 27279 carried a facility payment rate only. For 2027, CMS finalized the RUC-recommended practice expense inputs, which produce the new office rate. The $19,441 figure is before geographic adjustment, sequestration and patient cost sharing, and actual payment varies by locality.

Boulder – November 06, 2026 -- An estimated 3.29 to 3.98 million U.S. adults have severe hypertriglyceridemia, but only 2.43 to 2.88 million have been diagnosed, according to a white paper released by the National Triglyceride Alliance. The gap implies roughly 0.86 to 1.10 million adults who are undiagnosed.

The paper, titled "Hidden in Plain Sight: The Unseen Burden of Very High Triglycerides," was supported by Ionis Pharmaceuticals. Patient, care partner, clinical and advocacy contributors helped develop it. It defines the condition as triglycerides of 500 mg/dL or higher.

New York – November 06, 2026 -- Navina, an AI-powered clinical intelligence platform, has appointed Dr. Joshua Newman as Chief Medical Officer as its platform reaches more than 20,000 clinicians and care team members at over 1,300 U.S. clinics, supporting the care of more than five million patient lives.

Newman brings nearly 14 years of Salesforce healthcare leadership

Newman spent almost 14 years at Salesforce, where he served as SVP and Chief Medical Officer and as SVP and Global GM of Healthcare and Life Sciences. In that role he built the company's healthcare business and its relationships with health systems and payers.

Most recently, he was Chief Strategy Officer at Alleviate.care, a physician-led hospice and palliative care organization. He began his career in clinical practice and served as an assistant professor of medicine at UCLA.

San Francisco – November 06, 2026 -- The Delta Dental Community Care Foundation has announced $16.3 million in Access to Care Grants for nonprofits providing oral health services to underserved populations. The funding covers the 15-state service area of Delta Dental of California and affiliates, plus Washington, D.C.

Foundation giving has passed $200 million since 2011

The foundation is the philanthropic arm of Delta Dental of California and affiliates. Since 2011 it has provided more than $200 million in funding and support to nonprofits working on oral health outcomes, health equity and barriers to care. The new round adds to that total.

Grants target three focus areas

The Access to Care Grants Program funds organizations in three categories:

THOUSAND OAKS – November 06, 2026 -- Amgen reported that Repatha (evolocumab) lowered the risk of fatal or nonfatal heart attack by 20% compared with ezetimibe in adults with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The real-world study followed 544,103 patients for up to four years and was published in The American Journal of Preventive Cardiology.

Four-year heart attack risk falls to 5.88% with Repatha versus 7.76% with ezetimibe

Among 225,048 patients with a baseline LDL-C measurement, the four-year cumulative risk of heart attack was 5.88% on Repatha and 7.76% on ezetimibe. Among patients without a baseline LDL-C measurement, the corresponding risks were 5.65% and 7.06%.

The primary outcome was fatal or nonfatal myocardial infarction. The hazard ratio was 0.80 (95% CI, 0.70-0.91).

DENVER – – November 06, 2026 -- Global Healthcare Exchange (GHX) opened early registration for GHX Summit 2027, offering savings of more than $600 per registration through February 12, 2027. The event runs May 10-13, 2027, at Loews Arlington Hotel in Arlington, Texas.

Providers, suppliers, distributors, ERP and GPO partners and industry organizations are expected to attend. GHX also opened nominations for the 2026 GHXcellence Awards.

GHX builds Summit 2027 around customer ideas from 77 organizations

The program extends September's vibeGHX event, where providers and suppliers built AI-powered prototypes. Seventy-seven organizations took part, each bringing real workflow challenges. Select winning teams will present their ideas live at Summit, and attendees can join another vibeGHX event.

Rockville, Md. – November 06, 2026 -- The HealthWell Foundation, a non-profit that has distributed more than $5.2 billion in financial assistance to underinsured Americans, has elected asset-management technology executive Eric J. Meltzer to its Board of Directors.

Meltzer brings 20 years of technology transformation experience from asset managers

Meltzer works as an independent consultant and advisor to mid-size and large asset managers. He partners with boards and executive leadership on enterprise-wide technology transformation and operational excellence. He previously held CTO and leadership roles at Waddell & Reed, Oppenheimer Funds, Inc., and Putnam Investments.

Santa Clarita – November 06, 2026 -- Bioness Medical, Inc. has named Burke Rehabilitation one of 10 clinics nationwide in the inaugural 2026 Bioness Clinic of Excellence program, and Burke is the only recipient in New York. Burke, a member of the Montefiore Health System, was cited for adopting rehabilitation technology, training clinicians and delivering patient-centered care.

Burke uses five Bioness systems for at least 30 patients per day

Burke deploys Vector, H200 Wireless, L300 Go Plus, BITS and BITS Balance across its inpatient and outpatient programs. The systems serve patients with neurological and orthopedic conditions, including stroke, spinal cord injury, balance deficits and concussion. The hospital says the tools support at least 30 patients per day working on strength, mobility, balance and upper-extremity function.

CHICAGO – November 06, 2026 -- Merge, part of Merative, is launching Merge Imaging, a cloud-native platform that unifies radiology, cardiology and clinical imaging workflows. It debuts at RSNA 2026 with AssignIQ, a new study-assignment tool, and new lung nodule and lesion tracking modules. The company says the package helps imaging teams scale reading capacity with their existing workforce.

AssignIQ matches studies to radiologists by subspecialty, credentials, workload and priority

AssignIQ extends MergeIQ, the platform's AI workflow orchestration layer, from prior-report intelligence into active study assignment. It builds on Merge Workflow Orchestrator and routes each case to an available radiologist based on subspecialty, credentials, workload and case priority. Merge says practices can use it to balance assignments and make better use of existing capacity.